Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Kazumi EckensteinKnight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA.
Beyza CengizKnight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA.ORCID 0000-0002-8699-0118
Matthew E K ChangCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA.ORCID 0000-0001-5859-388X
Jessie May CartierCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA.
Mark R FloryCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA.ORCID 0000-0002-6174-2708
George V ThomasKnight Cancer Institute, Oregon Health and Science University, Portland, OR 97201, USA.ORCID 0000-0001-7416-8840
Funding
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5M
Outreach/Diversity/Pipeline ProjectP20GM103440 · NIGMS · UNIVERSITY OF NEVADA RENO · PI Julia Petereit · 2012 to 2026
$58.0M
Tracking and EvaluationU54GM104944 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI KUMAR, PARVESH · 2013 to 2023
$39.6M
ULTRASOUND IMAGING COREP01HD034430 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI SAUNDERS, KIM ELIZABETH · 1997 to 2017
$20.7M
Developing novel polytherapies for Non-Clear Cell Renal Cell CarcinomaR01CA250378 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI George Victor Thomas · 2021 to 2026
$1.9M
Determining how autophagy mediates resistance to cancer therapiesR21CA222455 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI THOMAS, GEORGE VICTOR · 2018 to 2019
$363k
Novel Treatment Strategies for CancerR21CA259440 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI THOMAS, GEORGE VICTOR · 2021 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mitochondrial Translation Inhibition Uncovers a Critical Metabolic-Epigenetic Interface in Renal Cell Carcinoma. · full record | OpenQuestion